* Dimension Therapeutics receives positive opinion for European orphan drug designation for DTX301 for treatment of ornithine transcarbamylase (OTC) deficiency
The post BRIEF-Dimension Therapeutics to submit investigational new drug application for DTX301 appeared first on NASDAQ.